Australian Pharmaceutical Industry Says Export, Sales Figures Mask Trouble On The Horizon
This article was originally published in PharmAsia News
Australia’s pharmaceutical industry says it faces hard times, despite a recent report highlighting sales and exports. But challenges are expanding for many companies that face patent expirations, paving the way for generic manufacturers to drive prices down.
You may also be interested in...
Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.
A China-based IVD company, spun out of an Australian medical research institute, is seeking investors to support its plans for the 2018 launch its first two point-of-care tests for patients with infectious diseases including HIV and viral hepatitis.
Speakers from the legal, corporate and contract research sectors discussed the fast-moving changes that are impacting the legal and regulatory aspects of doing business in China at the recent AusBiotech conference in Melbourne, providing a broad range of advice for Australian and other pharma and biotech companies wanting to enter the rapidly expanding Chinese life sciences market.